Part B. In Vivo Activities: Prolongation of Action with Protamine Zinc
The elucidation of the structure of somatostatin (GH release-inhibiting factor — SRIF) (Brazeau et al., 1973) and the demonstration that it is effective in inhibiting insulin and glucagon release by direct effects on the pancreas (Koerker et al., 1974) has resulted in a number of attempts to develop a long-acting preparation for potential clinical use. The duration of action of SRIF is limited to 5–10 minutes after intravenous administration (Brazeau et al., 1973) and to a maximum of 20–30 minutes after subcutaneous injection (Brazeau et al., 1974a; Martin, 1974) in the rat. Similar findings are reported in primates, including man.
KeywordsMorphine Model Montreal General Hospital Secretory Burst SRIF Analog Minor Structural Modification
Unable to display preview. Download preview PDF.